This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Last Week Saw Record Weekly Inflow: Top & Flop ETFs
by Sanghamitra Saha
News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 news infused $44.5 billion into the stock market last week -- its biggest weekly inflow ever, per BofA, as quoted on MarketWatch.
Moderna's (MRNA) Coronavirus Vaccine Shows 94.5% Efficacy Rate
by Zacks Equity Research
Moderna's (MRNA) COVID-19 vaccine candidate mRNA-1273 proves its vaccine efficacy of 94.5% in the late-stage COVE study. The stock appreciates in pre-market trading following this news.
Positive Developments on COVID-19 Treatment Front
by Zacks Equity Research
Positive Developments on COVID-19 Treatment Front.
Moderna (MRNA) Covid Drug Proves 94.5% Efficacy
by Mark Vickery
The company now intends on filing for emergency authorization in the United States. Shares are up for MRNA 14% in the early market on the news.
The Zacks Analyst Blog Highlights: Pfizer, Hain Celestial, Pilgrim's Pride, United Natural Foods and Tyson Foods
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Hain Celestial, Pilgrim's Pride, United Natural Foods and Tyson Foods
J&J (JNJ) Expands BARDA Deal for COVID-19 Vaccine Development
by Zacks Equity Research
J&J's (JNJ) ENSEMBLE study on its COVID-19 vaccine candidate is expected to enroll 60,000 adult participants.
6 Best-Performing Leveraged ETF Areas of Last Week
by Sanghamitra Saha
Last week was all about vaccine hopes and a stupendous Wall Street rally.
The S&P Hits a New High and the Dow Eyes Its Own 30K Milestone
by David Borun
Stocks continue to rally broadly on more good vaccine news, even as Covid-19 cases and deaths spike.
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch
by Daniel Laboe
There is now a more defined light at the end of this pandemic tunnel. Still, we are not out of the woods yet.
The Zacks Analyst Blog Highlights: Pfizer, AXT, Glu Mobile and iClick Interactive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, AXT, Glu Mobile and iClick Interactive
Pharma Stock Roundup: PFE Coronavirus Data, FDA Emergency Tag for LLY COVID-19 Drug
by Kinjel Shah
Eli Lilly (LLY) and Pfizer (PFE) provide updates on their coronavirus vaccine/antibody candidates.
Coronavirus Fears to Boost Packaged Food Sales: 4 Picks
by Ritujay Ghosh
The Hain Celestial Group, Inc. (HAIN), United Natural Foods, Inc. (UNFI) and Tyson Foods, Inc. (TSN) may one again witness a surge in the demand for their products as surging coronavirus cases may once again compel people to confine themselves indoors.
5 Stocks Poised to Soar on Strong Relative Price Strength
by Nilanjan Choudhury
Clean Harbors (CLH(, Harley-Davidson (HOG), Newell Brands (NWL), Regions Financial (RF) and Tapestry (TPR) are five stocks with explosive relative price strength.
This is Why Energy Stocks Suffered a Sharp Selloff Yesterday
by Nilanjan Choudhury
Following the surprise rise in crude stockpiles, some of the biggest casualties of the S&P 500 were energy-related names like Phillips 66 (PSX), Marathon Petroleum (MPC), Hess (HES), Valero Energy (VLO) and Occidental Petroleum (OXY).
Buy Walmart Stock for Growth and Safety Before Q3 Earnings?
by Benjamin Rains
Walmart's drive to compete in an age where consumers want as many options as possible sets it up nicely for the future...
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Will Vaccine Help Mastercard (MA) Regain Its Lost Business?
by Zacks Equity Research
The COVID-19 vaccine formulated by Pfizer is likely to help relieve the fear against travelling in crowds. This should spur travel demand and aid Mastercard (MA) to recover the lost cross-border sales.
AstraZeneca's (AZN) Calquence Fails in Coronavirus Study
by Zacks Equity Research
AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.
Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress
by Zacks Equity Research
Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.
Sector ETFs & Stocks to Buy This November
by Sweta Killa
November has been the second-best month for the Dow Jones since 1950, the Nasdaq since 1971 and Russell 2000 since 1979. The month is the best for the S&P 500 since 1950.
Stock Market News for Nov 12, 2020
by Zacks Equity Research
Stocks ended mostly higher on Wednesday, with the tech sector recovering from the losses made earlier in the week, after growing cases of coronavirus once again raised fears in the minds of investors.
The Zacks Analyst Blog Highlights: Pfizer, Visa, Mastercard, American Express and Discover Financial Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Visa, Mastercard, American Express and Discover Financial Services
Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.
3 Cheap Tech Stocks Under $10 to Buy on Bullish Vaccine Outlook
by Benjamin Rains
Let's dive into three tech stocks that are trading for under $10 per share that investors might want to buy amid broader bullish vaccine sentiment in the market...
Equilibrium Descends on Mixed Market Indexes: AAPL, DIS & More
by Mark Vickery
The re-balancing from a big rush out of tech into cyclical stocks earlier this week was in play Wednesday.